Silencing HSF1 by short hairpin RNA decreases cell proliferation and enhances sensitivity to hyperthermia in human melanoma cell lines

Journal of Dermatological Science

Volumn 60, Issue 3, 2010, Pages 187-192

  Nakamura, Yoshitaka ^a   Fujimoto, Mitsuaki ^a   Hayashida, Naoki ^a   Takii, Ryosuke ^a   Nakai, Akira ^a   Muto, Masahiko ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Heat shock proteins (Hsps); Heat shock transcription factor 1 (HSF1); Hyperthermia; Melanoma

Indexed keywords

DACARBAZINE; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; GENE SILENCING; HEAT SHOCK; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BASE SEQUENCE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DACARBAZINE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; G1 PHASE; GENE SILENCING; HEAT-SHOCK RESPONSE; HUMANS; HYPERTHERMIA, INDUCED; KERATINOCYTES; MELANOMA; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 78649520018     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2010.09.009     Document Type: Article

References (41)

1. Howe H.L., Wingo P.A., Thun M.J., Ries L.A., Rosenberg H.M., Feigal E.G., et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001, 93:824-842.
2. Bevona C., Sober A.J. Melanoma incidence trends. Dermatol Clin 2002, 20:589-595.
3. Dreiling L., Hoffman S., Robinson W.A. Melanoma: epidemiology, pathogenesis, and new modes of treatment. Adv Intern Med 1996, 41:553-604.
4. Balch C.M., Buzaid A.C., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3635-3648.
5. Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev CD001215.
6. Becker J.C., Kampgen E., Brocker E.B. Classical chemotherapy for metastatic melanoma. Clin Exp Dermatol 2000, 25:503-510.
7. Chapman P.B., Einhorn L.H., Meyers M.L., Saxman S., Destro A.N., Panageas K.S., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in the patients with metastatic melanoma. J Clin Oncol 1999, 17:2745-2751.
8. Parsell D.A., Lindquist S. The function of heat shock proteins in stress tolerance: degradation and reactivation of damaged protein. Annu Rev Genet 1993, 27:437-496.
9. Westerheide S.D., Morimoto R.I. Heat shock response modulators as therapeutic tools for disease of protein conformation. J Biol Chem 2005, 280:33097-33100.
10. Balch W.E., Morimoto R.I., Dillin A., Kelly J.W. Adapting proteostasis for disease intervention. Science 2008, 319:916-919.
11. Morimoto R.I. Regulation of the heat shock transcription response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev 1998, 12:3788-3796.
12. McMillan D.R., Xiao X., Shao L., Graves K., Benjamin I.J. Targeted disruption of heat shock transcription factor 1 abolishes thermotolerance and protection against heat-inducible apoptosis. J Biol Chem 1998, 273:7523-7528.
13. Zhang Y., Huang L., Zhang J., Moskophidis D., Mivechi N.F. Targeted disruption of hsf1 leads to lack of thermotolerance and defines tissue-specific regulation for stress-inducible Hsp molecular chaperones. J Cell Biochem 2002, 86:376-393.
14. Inouye S., Katsuki K., Izu H., Fujimoto M., Sugahara K., Yamada S., et al. Activation of heat shock gene is not necessary for protection by heat shock transcription factor 1 against cell death due to a single exposure to high temperatures. Mol Cell Biol 2003, 23:5882-5895.
15. Tanabe M., Kawazoe Y., Takeda S., Morimoto R.I., Nagata K., Nakai A. Disruption of the HSF3 gene results in sever reduction of heat shock gene expression and loss of thermotolerance. EMBO J 1998, 17:1750-1758.
16. Hsu A.L., Murphy C.T., Kenyon C. Regulation of against and age-related disease by DAF-16 and heat-shock factor. Science 2003, 300:1142-1145.
17. Morley J.F., Morimoto R.I. Regulation of longevity in Caenorhabditis elegans by heat shock factor and molecular chaperones. Mol Biol Cell 2004, 15:657-664.
18. Fujimoto M., Takaki E., Hayashi T., Kitaura Y., Tanaka Y., Inouye S., et al. Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J Biol Chem 2005, 280:34908-34916.
19. Steele A.D., Hutter G., Jackson W.S., Heppner F.L., Borkowski A.W., King O.D., et al. Heat shock factor 1 regulates lifespan as distinct from disease onset in prion disease. Proc Natl Acad Sci USA 2008, 105:13626-13631.
20. Sakamoto M., Minamino T., Tiko H., Kayama Y., Zuo Y., Sano M., et al. Upregulation of heat shock transcription factor 1 plays a critical role in adaptive cardiac hypertrophy. Circ Res 2006, 99:1411-1418.
21. Tanaka K., Namba T., Arai Y., Fujimoto M., Adachi H., Sobue G., et al. Genetic evidence for protective role for heat shock factor 1 and heat shock protein 70 against colitis. J Biol Chem 2007, 282:23240-23252.
22. Nakai A., Suzuki M., Tanabe M. Arrest of spermatogenesis in mice expressing an active heat shock transcription factor 1. EMBO J 2000, 19:1545-1554.
23. Izu H., Inouye S., Fuhimoto M., Shiraishi K., Naito K., Nakai A. Heat-shock transcription factor 1 is involved in quality control mechanisms in male germ cells. Biol Reprod 2004, 70:18-24.
24. Hayashida N., Inouye S., Fujimoto M., Tanaka Y., Izu H., Takaki E., et al. A novel HSF1-mediated death pathway that is suppressed by heat shock proteins. EMBO J 2006, 25:4773-4783.
25. Akerfelt M., Trouillet D., Mezger V., Sistonen L. Heat shock factors at a crossroad between stress and development. Ann N Y Acad Sci 2007, 1113:15-27.
26. Nakai A. Heat shock transcription factors and sensory placode development. BMB Rep 2009, 42:631-635.
27. Jolly C., Morimoto R.I. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000, 92:1564-1572.
28. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:761-772.
29. Calderwood S.K., Khaleque M.A., Sawyer D.B., Ciocca D.R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006, 31:164-172.
30. Hoang A.T., Huang J., Rudra-Ganguly N., Zheng J., Powell W.C., Rabindran S.K., et al. A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma. Am J Pathol 2000, 156:857-864.
31. Tang D., Khaleque M.A., Jones E.L., Theriault J.R., Li C., Wong W.H., et al. Expression of heat shock proteins and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and tumors in vivo. Cell Stress Chaperones 2005, 10:46-58.
32. Min J.N., Huang L., Zimonjic D.B., Moskophidis D., Mivechi N.F. Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors. Oncogene 2007, 26:5086-5097.
33. Dai C., Whitesell L., Rogers A.B., Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007, 130:1005-1018.
34. Fujimoto M., Hayashida N., Katoh T., Oshima K., Shinkawa T., Prakasam R., et al. A novel mouse HSF3 has the potential to activate non-classical heat shock genes during heat shock. Mol Biol Cell 2010, 20:106-116.
35. Lee Y.J., Lee H.J., Lee J.S., Jeoung D., Kang C.M., Base S., et al. A novel function for HSF1-induced mitotic exit failure and genomic instability through direct interaction between HSF1 and Cdc20. Oncogene 2008, 27:2999-3009.
36. Rossi A., Ciafre S., Balsamo M., Pierimarchi P., Santoro M.G. Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochomotherapy efficacy in cervical cancer. Cancer Res 2006, 65:7678-7685.
37. Middleton M.R., Lorigan P., Owen J., Ashcroft L., Lee S.M., Harper P., et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000, 82:1158-1162.
38. Shellman Y.G., Howe W.R., Miller L.A., Goldstein N.B., Pacheco T.R., Mahajan R.L., et al. Hyperthermia induces endoplasmic reticulum-mediated apoptosis in melanoma and non-melanoma skin cancer cells. J Invest Dermatol 2008, 128:949-956.
39. Sato M., Yamashita T., Ohkura M., Osai Y., Sato A., Takada T., et al. N-propionyl-cysteaminylphenol-magnetite conjugate (NPrCAP/M) is a nanoparticle for the targeted growth suppression of melanoma cells. J Invest Dermatol 2009, 129:2233-2241.
40. Page T.J., Sikder D., Yang L., Pluta L., Wolfinger R.D., Kodadek T., et al. Genome-wide analysis of human HSF1 signaling reveals a transcriptional program linked to cellular adaptation and survival. Mol Biosyst 2006, 2:627-639.
41. Whitesell L., Lindquist S. Inhibiting the transcription factor HSF1 as an anticancer strategy. Expert Opin Ther Targets 2009, 13:469-478.